---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023500"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:35.411711+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences reports Q2 2025 net loss of $1.7M, advances Phase 3 trial for PF614

## Summary
- Cash and equivalents $2.2M at June 30, 2025, down from $3.5M at Dec 31, 2024.
- Net loss $1.7M in Q2 2025 vs $2.0M loss in Q2 2024; R&D expenses rose to $1.9M from $0.9M.
- Federal grant revenue $1.4M in Q2 2025 vs $0.2M in Q2 2024, driven by MPAR study activity.
- Initiated pivotal Phase 3 trial (PF614-301) for post-surgical pain; Rho, Inc. engaged as CRO.
- Received $5.3M NIDA installment and U.S. patent allowance for OUD candidate PF9001.

## SEC filing metadata
- accession: 0001641172-25-023500
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000164117225023500/0001641172-25-023500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000164117225023500/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023500
- JSON: https://secwatch.observer/filing/0001641172-25-023500.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.